DrugPatentWatch Archives
Click here to return to the current data set
|
DrugPatentWatch concentrates deep knowledge on more than 6,400 small-molecule drugs and 2,300 generic ingredients from 1,700 branded and generic pharmaceutical companies and 700 suppliers, and more than 4,300 active and expired US patents and 74,000 international patents spanning 93 countries and regional patent offices. |
Tradename: EXELON
Summary for Tradename: EXELON
|
| |||||||||||
Clinical Trials for: EXELONA Double-Blind, Placebo-Controlled Crossover Study of Repeat Rivastigmine (Exelon®) Administration in Young Healthy Male Volunteers Status: Not yet recruiting Condition: Rivastigmine Toxicity Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type Status: Completed Condition: Alzheimer's Disease Rivastigmine and Huperzine A as Treatments for Cocaine Dependence Status: Recruiting Condition: Cocaine Dependence; Cocaine Addiction; Cocaine Abuse; Substance Abuse Rivastigmine as a Treatment for Methamphetamine Dependence Status: Completed Condition: Methamphetamine Dependence; Substance Abuse; Methamphetamine Abuse Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline Status: Completed Condition: Alzheimer Disease Study for the Tolerability of Exelon Patch (Rivastigmine) for Alzheimer's Disease (AD) Patients Status: Recruiting Condition: Alzheimer's Disease Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD) Status: Completed Condition: Parkinson's Disease Dementia Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Alzheimer's Dementia Status: Recruiting Condition: Alzheimer's Dementia Exelon Patch and Combination With Memantine Comparative Trial Status: Completed Condition: Alzheimer's Disease Effects of Exercise and Rivastigmine on Quality of Life of Alzheimer's Disease Patients Status: Completed Condition: Alzheimer Disease Courtesy of ClinicalTrials.org See more clinical trials for this drug | ||||||||||||
Glossary
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist_Flag | Patent Expiration | Exclusivity Expiration | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novartis | EXELON | rivastigmine | FILM, EXTENDED RELEASE; TRANSDERMAL | 022083 | Jul 6, 2007 | RX | No | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Novartis | EXELON | rivastigmine | FILM, EXTENDED RELEASE; TRANSDERMAL | 022083 | Jul 6, 2007 | RX | No | 4,948,807 | Y | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Novartis | EXELON | rivastigmine | FILM, EXTENDED RELEASE; TRANSDERMAL | 022083 | Jul 6, 2007 | RX | No | 5,602,176 | Y | Y | <disabled> | <disabled> | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Novartis | EXELON | rivastigmine | FILM, EXTENDED RELEASE; TRANSDERMAL | 022083 | Jul 6, 2007 | RX | No | 6,316,023 | Y | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| The preview shows a limited data set. Complete access is available with a Subscription | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Paragraph IV activity for: EXELON
| Drugname | Dosage | Strength | RLD | Submissiondate |
| rivastigmine | Transdermal System Extended-release | 4.6 mg/24 hr and 9.5 mg/24 hr | Exelon Patch | 4/27/2011 |
| rivastigmine tartrate | Oral Solution | 2 mg/mL | Exelon | 11/5/2004 |
| rivastigmine tartrate | Capsules | 1.5 mg, 3 mg, 4.5 mg and 6 mg | Exelon | 4/21/2004 |
« Back to Dashboard
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Connect with Social Media:
Copyright © 2002-2013 thinkBiotech LLC. ISSN: 2162-2639
`abc